|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
389,580,000 |
Market
Cap: |
45.17(B) |
Last
Volume: |
1,813,692 |
Avg
Vol: |
1,929,144 |
52
Week Range: |
$75.49 - $140.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 487 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
64,005 |
267,979 |
302,595 |
574,627 |
Total Sell Value |
$8,769,441 |
$35,482,928 |
$39,449,301 |
$69,910,840 |
Total People Sold |
6 |
8 |
13 |
15 |
Total Sell Transactions |
10 |
24 |
47 |
82 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Foletta Mark G |
Director |
|
2020-03-03 |
4 |
AS |
$270.63 |
$277,079 |
I/I |
(1,000) |
13,147 |
|
48% |
|
Moy Jeffrey |
EVP Operations |
|
2020-03-02 |
4 |
AS |
$278.10 |
$100,672 |
I/I |
(362) |
25,032 |
|
54% |
|
Doubleday Richard |
EVP Chief Commercial Officer |
|
2020-02-24 |
4 |
AS |
$275.99 |
$425,507 |
I/I |
(1,532) |
10,714 |
|
39% |
|
Pacelli Steven Robert |
EVP Strategy and Corporate Dev |
|
2020-02-24 |
4 |
AS |
$275.76 |
$425,323 |
D/D |
(1,531) |
74,624 |
|
39% |
|
Moy Jeffrey |
EVP Operations |
|
2020-02-18 |
4 |
AS |
$283.37 |
$1,893,318 |
I/I |
(6,599) |
25,220 |
|
29% |
|
Leach Jacob Steven |
EVP Chief Technology Officer |
|
2020-02-18 |
4 |
OE |
$9.78 |
$112,059 |
D/D |
11,458 |
122,563 |
|
- |
|
Collins Richard Alexander |
Director |
|
2020-02-18 |
4 |
AS |
$284.40 |
$1,137,600 |
I/I |
(4,000) |
5,304 |
|
29% |
|
Augustinos Nicholas |
Director |
|
2020-02-14 |
4 |
AS |
$283.80 |
$514,246 |
D/D |
(1,812) |
3,230 |
|
62% |
|
Sayer Kevin R |
President, CEO and Chairman |
|
2020-02-10 |
4 |
AS |
$240.97 |
$1,454,367 |
D/D |
(6,000) |
190,937 |
|
70% |
|
Murphy Patrick Michael |
SVP, Legal Affairs |
|
2020-02-10 |
4 |
AS |
$240.59 |
$120,295 |
D/D |
(500) |
26,447 |
|
70% |
|
Foletta Mark G |
Director |
|
2020-02-03 |
4 |
AS |
$236.84 |
$237,843 |
I/I |
(1,000) |
14,147 |
|
54% |
|
Doubleday Richard |
EVP Chief Commercial Officer |
|
2020-01-23 |
4 |
AS |
$233.17 |
$359,003 |
I/I |
(1,532) |
12,246 |
|
55% |
|
Pacelli Steven Robert |
EVP Strategy and Corporate Dev |
|
2020-01-23 |
4 |
AS |
$233.17 |
$358,971 |
D/D |
(1,532) |
76,155 |
|
55% |
|
Murphy Patrick Michael |
SVP, Legal Affairs |
|
2020-01-09 |
4 |
AS |
$235.01 |
$117,505 |
D/D |
(500) |
26,947 |
|
75% |
|
Skyler Jay S |
Director |
|
2020-01-03 |
4 |
AS |
$216.16 |
$5,621,816 |
I/I |
(25,806) |
30,417 |
|
88% |
|
Foletta Mark G |
Director |
|
2020-01-03 |
4 |
AS |
$217.61 |
$218,053 |
I/I |
(1,000) |
15,147 |
|
88% |
|
Altman Steven R |
Director |
|
2020-01-02 |
4 |
AS |
$216.23 |
$545,834 |
I/I |
(2,500) |
46,304 |
|
95% |
|
Pacelli Steven Robert |
EVP Strategy and Corporate Dev |
|
2019-12-23 |
4 |
AS |
$213.10 |
$326,576 |
D/D |
(1,532) |
77,687 |
|
- |
|
Doubleday Richard |
EVP Chief Commercial Officer |
|
2019-12-23 |
4 |
AS |
$212.93 |
$326,558 |
I/I |
(1,533) |
13,778 |
|
- |
|
Augustinos Nicholas |
Director |
|
2019-12-16 |
4 |
AS |
$206.14 |
$373,526 |
D/D |
(1,812) |
5,042 |
|
- |
|
Kahn Barbara |
Director |
|
2019-12-12 |
4 |
AS |
$202.22 |
$1,846,222 |
I/I |
(9,000) |
11,266 |
|
- |
|
Murphy Patrick Michael |
SVP, Legal Affairs |
|
2019-12-09 |
4 |
AS |
$223.31 |
$1,238,346 |
D/D |
(5,518) |
27,447 |
|
- |
|
Foletta Mark G |
Director |
|
2019-12-03 |
4 |
AS |
$221.34 |
$227,593 |
I/I |
(1,000) |
16,147 |
|
- |
|
Sayer Kevin R |
President, CEO and Chairman |
|
2019-12-02 |
4 |
AS |
$218.28 |
$2,213,684 |
D/D |
(10,000) |
202,937 |
|
- |
|
Pacelli Steven Robert |
EVP Strategy and Corporate Dev |
|
2019-11-22 |
4 |
AS |
$217.39 |
$333,300 |
D/D |
(1,532) |
79,219 |
|
- |
|
2306 Records found
|
|
Page 23 of 93 |
|
|